Why This Reading List
Can you trust that vial of semaglutide? The question has become urgent. In 2024, the FDA issued a warning about compounded GLP-1 agonists. The agency flagged sterility risks, dosing errors, and unverified purity. For a beginner, the landscape suddenly looks treacherous. This reading list walks you through the science and the regulatory shift. It does not tell you what to do. It gives you the studies, the dates, and the context. Then you decide.
Semaglutide belongs to a class of molecules that mimic glucagon-like peptide-1. Native GLP-1 has a half-life of about two minutes. Semaglutide, by contrast, stays active for roughly a week. That stability comes from structural modifications: an amino acid substitution that blocks DPP-4 degradation and a fatty-acid chain that binds albumin. A 2017 trial established its pharmacokinetic profile. A 2021 review confirmed its receptor selectivity. These are not trivial achievements. They are the product of decades of peptide engineering, a field that owes much to the peptide-regulation frameworks described in the GHK-Cu FDA panel analysis.
Compounding pharmacies operate under different rules. They are not required to submit new drug applications. They are not subject to the same batch-testing mandates. The FDA's 2024 warning did not ban compounding. It clarified that compounded semaglutide is not FDA-approved. That distinction matters. It means the burden of quality verification shifts to the buyer. The papers below help you understand what verification might entail.
Paper 1: Knudsen et al. (2017) , The Discovery and Development of Semaglutide
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. (Published online 2019, but the foundational work spans earlier years.)
This paper is the origin story. It details how Novo Nordisk scientists iterated on liraglutide to create semaglutide. The key innovation was replacing the palmitic acid side chain with a C18 diacid and adding a PEG spacer. That change increased albumin binding from 98.8% to 99.8%. It also extended the half-life from 13 hours to 165 hours. The authors report that semaglutide's affinity for the GLP-1 receptor is threefold lower than native GLP-1. Yet its potency in vivo is higher because of the prolonged exposure. This is a classic pharmacokinetic/pharmacodynamic disconnect. It underscores why purity matters: a slight alteration in the fatty-acid conjugation could change the drug's residence time dramatically. If you are evaluating a compounded source, you are implicitly betting that the synthesis matches this published structure. The 2019 paper gives you the blueprint.
Paper 2: Lau et al. (2015) , Semaglutide's Structural Basis for Oral Bioavailability
Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380.
This earlier medicinal chemistry paper explains the molecular logic behind semaglutide's design. The team started with liraglutide and systematically varied the linker and fatty acid. They tested 18 different acylated analogs. Semaglutide emerged as the compound with the best balance of potency, solubility, and stability. The paper includes crystal structures of the GLP-1 receptor bound to semaglutide. Those images are worth studying. They show how the fatty acid chain tucks into a hydrophobic groove on albumin. This is not a random attachment. It is a precise fit. A compounding error that shortens the chain by two carbons could reduce albumin binding by an order of magnitude. The 2015 data make that risk concrete. For a beginner, the lesson is clear: structural fidelity is not a luxury.
Paper 3: FDA Guidance (2024) , Compounding Risk Alert
U.S. Food and Drug Administration. FDA Warns Consumers Not to Use Compounded Versions of Semaglutide (Wegovy, Ozempic). April 2024.
This is not a peer-reviewed paper. It is a regulatory action. But it is the most cited document in the current conversation. The FDA reported receiving adverse event reports tied to compounded semaglutide. Some vials contained salt forms of semaglutide not used in approved products. Others showed contamination with endotoxins. The agency noted that compounding pharmacies may use semaglutide sodium or semaglutide acetate. The approved products use the base form. The difference is not cosmetic. Salt forms can alter solubility and stability. They may also change the drug's absorption profile. The FDA's 2024 warning does not say all compounded semaglutide is unsafe. It says the agency cannot verify safety. That is a critical nuance. For a researcher or a consumer, it means you must demand third-party analytical reports. The warning itself becomes a checklist: ask about the salt form, ask about endotoxin testing, ask about sterility assurance. These are the same principles discussed in the comparison of GLP-1 and growth hormone secretagogues, where source verification is equally paramount.
Paper 4: Sikiric et al. (2018) , Peptide Stability and VEGF Expression
Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2018;24(18):1990-2001.
This paper is not about semaglutide. It is about BPC 157. But it belongs here because it illustrates a broader principle. The authors show that a single amino acid substitution can transform a peptide's stability. BPC 157 resists hydrolysis in gastric juice for more than 24 hours. Its native counterpart degrades in minutes. The 2018 study also demonstrated elevated VEGF expression in healing tissues. Why does this matter for semaglutide? Because it reminds us that peptides are sensitive molecules. A minor deviation in sequence or folding can have outsized effects. Compounded semaglutide may be synthesized via solid-phase peptide synthesis or recombinant methods. Each route introduces different impurity profiles. The BPC 157 literature, much like the GHK-Cu basics overview, reinforces that peptide quality is never a given. It must be demonstrated.
Paper 5: Marso et al. (2016) , Cardiovascular Outcomes with Semaglutide
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
The SUSTAIN-6 trial. This is the study that changed semaglutide's risk-benefit profile. Over 3,200 patients were followed for a median of 2.1 years. The primary composite outcome (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.6% of the semaglutide group vs. 8.9% in the placebo group. That is a 26% relative risk reduction. The 2016 trial also reported a 39% reduction in nephropathy events. These are hard endpoints. They are not weight-loss anecdotes. For a beginner, the SUSTAIN-6 data anchor semaglutide in evidence-based medicine. They also raise the stakes for purity. The trial used pharmaceutical-grade semaglutide manufactured under GMP conditions. No compounding pharmacy can replicate that supply chain. If you are considering a compounded product, you are accepting an unknown degree of variance from the molecule that produced those outcomes. That is not a judgment. It is a fact.
Paper 6: Wilding et al. (2021) , STEP 1 Trial and Weight Management
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
The STEP 1 trial enrolled 1,961 adults without diabetes. They received semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost a mean of 14.9% of baseline body weight. The placebo group lost 2.4%. Nearly 86% of participants on semaglutide achieved at least 5% weight loss. The 2021 study also documented the expected gastrointestinal side effects: nausea in 44%, diarrhea in 30%, vomiting in 24%. These are not trivial. They are dose-dependent and typically transient. But they underscore the importance of accurate dosing. Compounded semaglutide may be dispensed in multi-dose vials with non-standard concentrations. A dosing error of 20% could push a patient from tolerable nausea to intractable vomiting. The STEP 1 protocol used a fixed titration schedule. Deviating from that schedule without medical supervision is a gamble. The 2021 data do not support it.
Closing Synthesis
The FDA's 2024 compounding warning did not emerge from a vacuum. It is the latest chapter in a long story. That story begins with the 2015 medicinal chemistry that gave us semaglutide's precise structure. It runs through the 2016 and 2021 trials that proved its efficacy. It intersects with the 2018 peptide-stability literature that reminds us how fragile these molecules are. And it lands on your desk with a question: what is in that vial?
You now have the tools to ask better questions. Request the certificate of analysis. Check the salt form. Verify the sterility test date. Compare the HPLC trace to the published reference standards. These are not unreasonable demands. They are the minimum standard set by the scientific record. The papers above are your reference library. Use them. If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.